Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06906367 · ClinicalTrials.gov registry record
A Study of Patients With Fabry Disease (US Specific)
A clinical trial of Fabry Disease, sponsored by Amicus Therapeutics.
- Recruiting
- Registry status
- 450
- Enrollment target
- 7
- Study locations
NCT06906367: Recruiting study of Fabry Disease, sponsored by Amicus Therapeutics.
NCT06906367 is a study of Fabry Disease that is actively recruiting participants, run by Amicus Therapeutics. The registered enrollment target is 450 participants, below the 529-participant average among 32 other Fabry Disease trials with a reported enrollment target (15% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06906367, a study of Fabry Disease, is actively recruiting participants, sponsored by Amicus Therapeutics.
- RECRUITING
- Registry status
- 450 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is an observational study to evaluate the effects of treatment on long-term effectiveness, safety, and health-related quality of life (HRQOL) in patients with Fabry disease, with a main focus on migalastat.
Primary Outcome
Annualized rate of change in eGFR(CKD-EPI) over time from study enrollment for the comparison between migalastat-treated and untreated patients who have risk factors for eGFR decline
Conditions Studied
Interventions
- DRUG migalastat HCl
- DRUG ERT
Study Locations (7)
Alabama
- UAB Nephrology Research Clinic at Paula Building - Birmingham
Arkansas
- Arkansas Children's Hospital - Little Rock
Georgia
- Emory Genetics - Atlanta
Missouri
- Washington University School of Medicine - St Louis
Pennsylvania
- UPMC Children's Hospital of Pittsburgh - Pittsburgh
Texas
- Renal Disease Research Institute - Dallas
Virginia
- Lysosomal and Rare Disorders Research and Treatment Center, Inc. - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2026-02-13 |
| Est. Completion | 2032-06 |
What NCT06906367 shows while recruiting
NCT06906367 is an observational study that tracks outcomes without assigning an intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, below the 529-participant average among 32 other Fabry Disease trials with a reported enrollment target (15% lower).
The record links to 1 condition, with Fabry Disease appearing as the primary indexed condition, and to 2 interventions - of which migalastat HCl is the first listed.
NCT06906367 lists 7 locations in 7 states (Alabama, Arkansas, Georgia).
Frequently Asked Questions
What is clinical trial NCT06906367 about?
NCT06906367 is a clinical study titled "A Study of Patients With Fabry Disease (US Specific)". This is an observational study to evaluate the effects of treatment on long-term effectiveness, safety, and health-related quality of life (HRQOL) in patients with Fabry disease, with a main focus on migalastat.
What is the current status of trial NCT06906367?
This trial is currently recruiting. The enrollment target is 450 participants. The study started on 2026-02-13. Estimated completion is 2032-06.
What conditions does trial NCT06906367 study?
This clinical trial studies the following conditions: Fabry Disease.
What interventions are being tested in trial NCT06906367?
The interventions under investigation include: migalastat HCl (DRUG), ERT (DRUG).
Who is sponsoring clinical trial NCT06906367?
This trial is sponsored by Amicus Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06906367 being conducted?
This trial has 7 study locations across Alabama, Arkansas, Georgia, Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fabry Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06906367's enrollment target sits among peer trials
450 4th of 32 higher than 29 of 32 other Fabry Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fabry Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
RECRUITING
-
Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study
RECRUITING
-
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
RECRUITING · Phase 3
-
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
RECRUITING · Phase 2
-
A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients
RECRUITING
-
A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI